3M littmann stethoscopes and eko collaborate to improve healthcare outcomes in patients

WORLD – 3M Littmann Stethoscopes, that deals in the production of medical devices and Eko digital innovations, a company specializing in artificial intelligence (AI), collaborate to deliver comprehensive healthcare solutions that will drive better patient outcomes. This is a collaboration that will see both companies try to meet the growing demand on auscultation in healthcare and the advancing digital technology by marrying 3M Littmann stethoscope technology with advanced Eko digital innovations. The collaboration has led to the development of an innovation, 3M Littmann Core digital stethoscope that offers clinicians access…

Read More

Max Healthcare collaborates with digital health solutions to launch a remote healthcare monitoring system

INDIA – Max Healthcare, a giant Indian based corporation in the healthcare sector, has launched an artificial intelligence (AI) powered device integrated patient monitoring framework, claimed to be the first in the country. The project was a success owing to the fact that Max Healthcare collaborated with digital health solutions, an Indian social business that uses technology and creativity to make high-quality health services. This was a move Max Healthcare undertook in a bid to expand its geography of care, allowing patients from across India and globally to stay connected…

Read More

Cuba inches closer to rolling out its vaccines soberana and Abdala

CUBA – The Caribbean island nation of 11 million people, which has been under a strict United States (US) trade embargo for decades, is in process of developing five experimental shots, including Soberana 02 and Abdala, which reached final-stage trials last month. With both Soberana and Abdala in stage-three clinical trials, Cuba is racing towards potentially becoming the first country in Latin America to develop its own shot against the coronavirus. The names of the vaccines reveal much about how Cuba sees its national effort, Soberana translates as “sovereign”, while…

Read More

BioNTech’s BNT111 phase 2 clinical trial makes progress as patient with advanced Melanoma treated

GERMANY – BioNTech, a German pharmaceutical company, has announced that the first patient has been treated in its BNT111 phase 2 cancer medication trial. Currently, the study is evaluating the Company’s therapeutic cancer vaccine candidate BNT111 in combination with Libtayo (cemiplimab), an anti-PD-1 monoclonal antibody, in patients with anti-PD1-refractory/relapsed unresectable Stage III or IV melanoma. Melanoma is a type of skin cancer that develops when melanocytes (the cells that give the skin its tan or brown color) start to grow out of control or can be refereed to hyperpigmentation. BNT111…

Read More

Pfizer’s tofacitinib gains usage traction based on data from Brazilian hospitalized patients

USA – Pfizer Inc. and The Academic Research Organization (ARO) from the Hospital Israelita Albert Einstein announced that the findings from the STOP-COVID study came out positive. The New England Journal of Medicine published positive findings from the study evaluating the efficacy and safety of oral Janus kinase (JAK) inhibitor tofacitinib in 289 hospitalized adult patients with COVID-19 pneumonia who were not on ventilation. Tofacitinib is a type of drug known as a Janus kinase (JAK) inhibitor that works by blocking the action of Janus kinase enzymes, which are involved…

Read More

Enhanze drug delivery technology brings ViiV Healthcare and Halozyme into a collaboration

UK – ViiV Healthcare, a global specialist HIV that is majorly owned by GlaxoSmithKline plc have announced a global collaboration and license agreement that gives exclusive access to Halozyme’s ENHANZE drug delivery technology, recombinant human hyaluronidase PH20 enzyme (rHuPH20), for specific targets used in the treatment and prevention of HIV. The license gives ViiV exclusive use of Halozyme’s proprietary rHuPH20 technology for four, specific HIV medicine targets that will expand opportunities for development of nearly all of ViiV’s pipeline assets. Under the terms of the agreement, ViiV Healthcare will make…

Read More

A boost for the NHS as the UK government announces a US$50.3m investment on AI research

UK – The UK government has announced a hefty £36bn funding boost for artificial intelligence (AI) research technologies in a bid to help the National Health System (NHS) transform the quality of healthcare. Funding will go toward the winners of the second wave of the NHS AI Lab’s AI in Health and Care Award. The AI award package also includes funding to support the research, development and testing of early phase, of promising ideas which could be used by the NHS in the future. Since the first round of the…

Read More

Bharat Biotech’s covaxin inches closer to the WHO’s emergency use listing

INDIA – Following an acceptance of its expression of interest by World Health Organization (WHO), Bharat’s covaxin could make it to the emergency use listing (EUL) after providing WHO with additional data. Bharat Biotech is a pioneering biotechnology company known for its world-class R&D and manufacturing capabilities and is the brainchild behind covaxin among numerous drugs. The pre-submission meeting of the vaccine maker with WHO has been planned in reference to the WHO EUL guidance document that was uploaded on the WHO website. A WHO EUL would open doors of…

Read More

Joseph Biden’s administration pumps in US$3.2bn for the development of a COVID-19 drug

US – The US government is taking another leap into the fight against COVID-19 through an investment worth US$3.2 billion to help develop antiviral therapy pills. This is part of the American Rescue Plan (ARP) government strategy to develop the next generation of COVID-19 treatments. ARP was developed to provide emergency grants, lending, and investment to hard-hit small businesses during the pandemic. This plan will provide more than $300 million for research and lab support, nearly $1 billion for preclinical and clinical evaluation, and nearly $700 million for development and…

Read More

Medtronic launches world’s smallest pacemaker

INDIA – Medtronic private limited, a global leader in medical technology, services, and solutions, has launched Micra AV the world’s first miniature-sized pacemaker. Micra AV is the first pacemaker that can sense atrial activity without a lead or device in the upper chamber of the heart. The new innovation has several additional internal atrial sensing algorithms which detect cardiac movement, allowing the device to adjust pacing in the ventricle to coordinate with the atrium. Micra AV provides Atrioventricular (AV) synchronous pacing therapy to patients with AV block, a type of…

Read More